MTOR and tuberous sclerosis: Results from a phase III, randomized, double-blind, placebo-controlled study (EXIST-3; NCT01713946) could tell us the efficacy and safety of 2 trough-ranges of everolimus (an mTOR inhibitor) as adjunctive therapy in patients with TSC who have refractory seizures.